Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841277 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
A Phase 1 study of Healthy and Renal Insufficiency, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT05841277: Completed Phase 1 study of Healthy and Renal Insufficiency, sponsored by Eli Lilly and Company.
NCT05841277 is a Phase 1 study of Healthy and Renal Insufficiency that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841277, a Phase 1 study of Healthy and Renal Insufficiency, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3819469 will also be evaluated in these participants. The study will last up to 17 weeks including screening period.
Primary Outcome
PK: AUC0-tlast of LY3819469
Conditions Studied
Interventions
- DRUG LY3819469
Study Locations (4)
Florida
- Floridian Clinical Research - Miami
- Advanced Pharma CR, LLC - Miami
- Omega Research Consultants - Orlando
Minnesota
- Nucleus Networks - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 1 |
What the finished NCT05841277 record still lists
NCT05841277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY3819469 is the first listed.
NCT05841277 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05841277 about?
NCT05841277 is a clinical study titled "A Study of LY3819469 in Participants With Impaired and Normal Renal Function". The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability...
What is the current status of trial NCT05841277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-04-25. Estimated completion is 2024-01-09.
What conditions does trial NCT05841277 study?
This clinical trial studies the following conditions: Healthy, Renal Insufficiency.
What interventions are being tested in trial NCT05841277?
The interventions under investigation include: LY3819469 (DRUG).
Who is sponsoring clinical trial NCT05841277?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05841277 being conducted?
This trial has 4 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05841277's enrollment target sits among peer trials
26 760th of 1090 higher than 314 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI